EUVIMEDEUVIMED entdecken
Metaanalyse

SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes

Pradip Mukhopadhyay iD, Debmalya Sanyal, Purushottam Chatterjee, Kaushik Pandit, Sujoy Ghosh iD

The Journal of Clinical Endocrinology & Metabolism · 14.07.2023 · 108 (8) · 2134-2140

DOI: 10.1210/clinem/dgad113 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.02.2023. Verfasst von Pradip Mukhopadhyay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Myocardial Infarction, Stroke. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have recently been recommended as preferred agents for management of hyperglycemia in type 2 diabetes, primarily based on their ability to reduce a composite of major cardiovascular adverse events (3-point major adverse cardiovascular events [MACE]), predominantly by reducing cardiovascular death. However, reduction of the individual components, myocardial infarction (MI), or stroke (fatal and nonfatal) events have not been well explored.

Methods

In this meta-analysis, we included data available from cardiovascular outcome trials only, which were event-driven, randomized, and placebo-controlled. Pooled efficacy outcomes included Mantel Haenszel (MH) risk ratio using fixed model (with 95% CI) for fatal and nonfatal MI, stroke, and total MI and stroke.

Findings

Data from 4 eligible trials included 42,568 subjects. Total MACE, MI, and stroke were reported in 4176, 2157, and 1288 subjects, respectively. SGLT2is did not significantly reduce either MI or stroke individually or in totality. The MH risk ratio (95% CI) for fatal and nonfatal MI and stroke with different SGLT2is was found to be 0.93 (95% CI, 0.85-1.01) and 1.00 (95% CI, 0.89-1.11), respectively. For total atherosclerotic cardiovascular disease (ASCVD) events, MH risk ratio (95% CI) was 0.95 (95% CI, 0.89-1.02). For all nonfatal ASCVD (combined nonfatal MI and nonfatal stroke), MH risk ratio (95% CI) was 0.94 (95% CI, 0.88-1.02).

Interpretation

SGLT2is reduce MACE without any discernable significant reduction of the incidence of MI or stroke (fatal and nonfatal), probably implicating mechanisms unrelated to anti-atherogenic effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsMyocardial InfarctionStrokeCardiovascular SystemAtherosclerosisCardiovascular DiseasesHumans

Stichwörter der Autor:innen

ASCVDSGLT 2 inhibitorsmyocardial infarctionstroke

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India.
  • Department of Endocrinology, KPC Medical College & Hospital, 1F, Raja Subodh Chandra Mallick Road, Jadavpur, Kolkata, West Bengal 700032, India.
  • Department of Endocrinology, Apollo Gleneagles Hospital, 58 Canal Circular Road, Kolkata, West Bengal 700054.

ORCID-Profile: Pradip Mukhopadhyay, Sujoy Ghosh

Zitieren

APA

Mukhopadhyay, P., Sanyal, D., Chatterjee, P., Pandit, K., & Ghosh, S. (2023). SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 108(8), 2134-2140. https://doi.org/10.1210/clinem/dgad113

Vancouver

Mukhopadhyay P, Sanyal D, Chatterjee P, Pandit K, Ghosh S. SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2023;108(8):2134-2140. doi:10.1210/clinem/dgad113

BibTeX
@article{Mukhopadhyay2023,
  author = {Mukhopadhyay, Pradip and Sanyal, Debmalya and Chatterjee, Purushottam and Pandit, Kaushik and Ghosh, Sujoy},
  title = {SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {8},
  pages = {2134--2140},
  doi = {10.1210/clinem/dgad113}
}
Kostenlos starten →